Chris Arthur

2.9k total citations · 2 hit papers
34 papers, 1.9k citations indexed

About

Chris Arthur is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Chris Arthur has authored 34 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 17 papers in Genetics and 9 papers in Rheumatology. Recurrent topics in Chris Arthur's work include Chronic Lymphocytic Leukemia Research (16 papers), Chronic Myeloid Leukemia Treatments (14 papers) and Eosinophilic Disorders and Syndromes (9 papers). Chris Arthur is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Chronic Myeloid Leukemia Treatments (14 papers) and Eosinophilic Disorders and Syndromes (9 papers). Chris Arthur collaborates with scholars based in Australia, United States and United Kingdom. Chris Arthur's co-authors include Andrew Grigg, Timothy P. Hughes, Kevin Lynch, Susan Branford, Zbigniew Rudzki, Kerry Taylor, Richard Herrmann, John F. Seymour, David Joske and Jeff Szer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Chris Arthur

33 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

2003 561 citations Susan Branford, Zbigniew Rudzki et al. Blood profile →
High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

2002 517 citations Susan Branford, Zbigniew Rudzki et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chris Arthur Australia	16	1.5k	1.1k	824	227	182	34	1.9k
Markus Pfirrmann Germany	22	1.9k 1.3×	1.7k 1.5×	967 1.2×	227 1.0×	271 1.5×	71	2.5k
Mari McQuitty United States	10	1.3k 0.9×	1.7k 1.5×	587 0.7×	220 1.0×	37 0.2×	11	2.1k
Mauro Fiacchini Italy	22	966 0.6×	497 0.4×	190 0.2×	398 1.8×	149 0.8×	57	1.5k
P.E. Dorlhiac‐Llacer Brazil	12	757 0.5×	523 0.5×	303 0.4×	141 0.6×	117 0.6×	20	986
Harry Iland Australia	18	838 0.6×	550 0.5×	161 0.2×	260 1.1×	77 0.4×	61	1.5k
K. B. McCredie United States	22	1.1k 0.8×	439 0.4×	168 0.2×	444 2.0×	432 2.4×	52	1.7k
Masamitsu Yanada Japan	27	2.0k 1.4×	456 0.4×	178 0.2×	366 1.6×	1.0k 5.5×	121	2.5k
Pierluigi Rossi Ferrini Italy	18	655 0.4×	458 0.4×	205 0.2×	168 0.7×	79 0.4×	56	1.1k
Sherry Pierce United States	16	680 0.5×	527 0.5×	211 0.3×	157 0.7×	202 1.1×	43	1.0k
Francesco Nobile Italy	21	846 0.6×	516 0.5×	58 0.1×	221 1.0×	227 1.2×	74	1.4k

Countries citing papers authored by Chris Arthur

Since Specialization

Citations

This map shows the geographic impact of Chris Arthur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Arthur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Arthur more than expected).

Fields of papers citing papers by Chris Arthur

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Arthur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Arthur. The network helps show where Chris Arthur may publish in the future.

Co-authorship network of co-authors of Chris Arthur

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Arthur. A scholar is included among the top collaborators of Chris Arthur based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Arthur. Chris Arthur is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lindsay, Julian, Jad Othman, Sebastiaan J. van Hal, et al.. (2021). SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation. Open Forum Infectious Diseases. 8(11). ofab502–ofab502. 11 indexed citations

Lindsay, Julian, Jad Othman, Michelle K. Yong, et al.. (2021). Dynamics of Epstein–Barr virus on post‐transplant lymphoproliferative disorders after antithymocyte globulin‐conditioned allogeneic hematopoietic cell transplant. Transplant Infectious Disease. 23(5). e13719–e13719. 7 indexed citations

Bannerji, Rajat, Sam Yuen, Tycel Phillips, et al.. (2021). POLATUZUMAB VEDOTIN + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL. Hematological Oncology. 39(S2). 3 indexed citations

Lindsay, Julian, Jad Othman, Ian Kerridge, et al.. (2020). Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre‐transplant predictors of survival, reactivation, and spontaneous clearance. Transplant Infectious Disease. 23(3). e13548–e13548. 8 indexed citations

Lindsay, Julian, Indy Sandaradura, Chris Arthur, et al.. (2017). Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation. Journal of Antimicrobial Chemotherapy. 72(12). 3414–3419. 40 indexed citations

Arthur, Chris, Jaroslav Čermák, Jacques Delaunay, et al.. (2012). Post hoc analysis of relationship between baseline white blood cell count and survival outcome in a randomized phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.. Journal of Clinical Oncology. 30(15_suppl). 6559–6559. 2 indexed citations

Pasricha, Sant‐Rayn, Andrew Grigg, John Catalano, et al.. (2008). A multicenter phase 2 study of risk‐adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma. Cancer. 113(11). 3192–3198. 9 indexed citations

Mitchell, Paul, Paula Marlton, Andrew Grigg, et al.. (2008). A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma. Leukemia & lymphoma. 49(5). 924–931. 7 indexed citations

Spencer, Andrew, Kate Reed, & Chris Arthur. (2007). Pilot study of an outpatient‐based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Internal Medicine Journal. 37(11). 760–766. 29 indexed citations

10.

Branford, Susan, Timothy P. Hughes, Alvin Milner, et al.. (2007). Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near‐complete cytogenetic response to interferon‐α. Cancer. 110(4). 801–808. 7 indexed citations

11.

Wolf, Max, Mark Bentley, Paula Marlton, et al.. (2006). Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma. Leukemia & lymphoma. 47(11). 2344–2350. 20 indexed citations

12.

Branford, Susan, Zbigniew Rudzki, Andrew Grigg, et al.. (2004). The Frequency of Detection of BCR-ABL Mutations in Imatinib Treated Patients with Chronic Phase CML Who Attain a Complete Cytogenetic Response (CCR) Does Not Diminish with Increasing Duration of CCR but the Associated Loss of Response Is Usually Gradual.. Blood. 104(11). 271–271. 2 indexed citations

13.

Branford, Susan, Zbigniew Rudzki, Ian Parkinson, et al.. (2003). Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 102(1). 276–283. 561 indexed citations breakdown →

14.

Branford, Susan, Zbigniew Rudzki, Andrew Harper, et al.. (2003). Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 17(12). 2401–2409. 118 indexed citations

15.

Solomon, Benjamin, John Moore, Chris Arthur, & H. Miles Prince. (2001). Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters. European Journal of Cancer. 37(18). 2379–2384. 30 indexed citations

16.

Favaloro, Emmanuel J., et al.. (2000). Possibility of potential VWD misdiagnosis or misclassification using LIA technology and due to presence of rheumatoid factor. American Journal of Hematology. 66(1). 53–56. 20 indexed citations

17.

Roach, Paul, et al.. (1998). Comparison of thallium‐201 and gallium‐67 scintigraphy in the evaluation of non‐Hodgkin's lymphoma. Australian and New Zealand Journal of Medicine. 28(1). 33–38. 10 indexed citations

18.

Hughes, Timothy P., Andrew Grigg, Jeff Szer, et al.. (1997). Mobilization of predominantly Philadelphia chromosome‐negative blood progenitors using cyclophosphamide and rHUG‐CSF in early chronic‐phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control. British Journal of Haematology. 96(3). 635–640. 10 indexed citations

19.

Favaloro, Emmanuel J., et al.. (1996). A survey of heparin monitoring in australasia. Pathology. 28(4). 343–347. 5 indexed citations

20.

Arthur, Chris & James P. Isbister. (1987). Iron Deficiency. Drugs. 33(2). 171–182. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact